sexta-feira, 6 de novembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 18, 2026

Communiqué de presse : Le venglustat de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3

View original at globenewswire.com
Communiqué de presse : Le venglustat de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3 Le venglustat de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3 Paris, le 18 mars 2026…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The positive results from the LEAP2MONO study are an encouraging advancement in the research and development process

    60% confidence

  • Venglustat was generally well tolerated with no new safety signals compared to previous studies

    60% confidence

  • Venglustat has the potential to slow the progression of Gaucher disease type 3 by inhibiting abnormal accumulation of glycosphingolipids and its pathophysiological consequences

    60% confidence

  • Venglustat works by reducing abnormal accumulation of glycosphingolipids and is designed to cross the blood-brain barrier to target the underlying pathology causing neurological effects of GD3

    60% confidence

  • Sanofi will continue to collaborate with the FDA to advance this potential therapeutic option

    60% confidence

  • There is currently no approved treatment for the neurological symptoms of Gaucher disease type 3

    60% confidence

  • Venglustat was generally well tolerated with no new safety signals compared to previous studies

    60% confidence

  • The positive results from the LEAP2MONO study are an encouraging advance in the research and development process, and we will continue to collaborate with the FDA to advance this potential treatment option

    60% confidence

  • There is no approved treatment for neurological symptoms of Gaucher disease type 3

    60% confidence

  • This regulatory milestone recognizes the significant unmet medical need for people living with Gaucher disease type 3, particularly those experiencing progressive neurological deterioration

    60% confidence

  • This regulatory milestone recognizes the significant unmet medical need for people living with Gaucher disease type 3, particularly those experiencing progressive neurological deterioration

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,996
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,996 factos verificados com a fonte5,552 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Communiqué de presse : Le venglustat de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3 — Source | Via News | pt.VIA.NEWS